Immune-checkpoint inhibitors, a mainstay of treatment of solid tumors, rarely lead to activation of the host immune system against another target, causing autoimmune inflammation of other end organs known as immune-related adverse events (ir-AEs). When ir-AEs ... ...

请注册登录后继续浏览